CSBio CSBio

X
[{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evotec and BMS Expand IPSC Collaboration","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Evotec"}]

Find Novel Neurology Drugs in Clinical Development in GERMANY

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            This partnership pursues an innovative approach to identifying and creating novel medicines using several of Evotec's technology technologies in tandem with the human iPSC-based platform.

            Lead Product(s): Induced pluripotent stem cells

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Bristol Myers Squibb

            Deal Size: $6.0 million Upfront Cash: Undisclosed

            Deal Type: Collaboration January 07, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY